Wexford Capital’s Tourmaline Bio TRML Stock Holding History

Wexford Capital’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-63,610	Closed	-$968K	–	321
2025 Q1	$968K	Buy	63,610 +43,000	+209%	+$689K	0.25%	77
2024 Q4	$418K	Buy	+20,610	New	+$519K	0.07%	114

Other funds holding TRML

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Wexford Capital's TRML Position: Q2 2025 in Review

Wexford Capital sold out of Tourmaline Bio (TRML) in Q2 2025, closing a stake of 63,610 shares — an estimated $968K sold.

Wexford Capital first reported a position in TRML in Q4 2024 and held it in 2 quarters. The position peaked at $968K in Q1 2025. 108 funds tracked by Wall St. Rank hold TRML as of Q2 2025.

Wexford Capital reported no remaining Tourmaline Bio position as of Q2 2025 after selling out during the quarter.
Wexford Capital sold 63,610 Tourmaline Bio shares in Q2 2025, an estimated $968K.
Wexford Capital first reported a position in Tourmaline Bio in Q4 2024 and held it in 2 quarters.
Wexford Capital's Tourmaline Bio position peaked at $968K in Q1 2025.
108 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2025.

Based on Wexford Capital's 13F filing for Q2 2025, filed 14 Aug 2025.